Zacks Research Lowers Earnings Estimates for Haemonetics

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research lowered their Q3 2027 earnings per share estimates for shares of Haemonetics in a research note issued to investors on Wednesday, January 29th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $1.30 for the quarter, down from their prior forecast of $1.31. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

A number of other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective on the stock. Barrington Research reiterated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research report on Friday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research note on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and an average target price of $108.78.

Haemonetics Price Performance

HAE stock opened at $69.53 on Friday. Haemonetics has a 1 year low of $67.26 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of 28.85, a P/E/G ratio of 1.06 and a beta of 0.41. The company has a 50 day simple moving average of $79.26 and a 200 day simple moving average of $79.45.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $0.99 earnings per share.

Institutional Trading of Haemonetics

Several large investors have recently made changes to their positions in HAE. Rhumbline Advisers increased its stake in Haemonetics by 0.6% during the 4th quarter. Rhumbline Advisers now owns 159,262 shares of the medical instruments supplier’s stock valued at $12,435,000 after purchasing an additional 1,024 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Haemonetics by 166.7% during the fourth quarter. Vontobel Holding Ltd. now owns 13,011 shares of the medical instruments supplier’s stock worth $1,016,000 after acquiring an additional 8,133 shares in the last quarter. Van ECK Associates Corp acquired a new stake in shares of Haemonetics in the 4th quarter worth about $3,094,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Haemonetics by 0.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock worth $62,802,000 after acquiring an additional 5,668 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Haemonetics in the 4th quarter valued at about $319,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.